STA363
Chronic Low Back Pain due to Lumbar Disc Herniation (LDH)
Key Facts
About Stayble Therapeutics
Stayble Therapeutics is a focused, clinical-stage company dedicated to developing STA363, a unique intradiscal injection for chronic pain from lumbar disc herniation (LDH). Its mission is to provide a simple, effective therapeutic option for millions of patients for whom pain medication and physiotherapy have failed, potentially avoiding the need for major surgery. The company's strategy hinges on successfully navigating clinical trials for STA363 to establish it as a leading second-line, minimally invasive treatment. Currently in Phase 1b, Stayble is pre-revenue, with its value and prospects intrinsically tied to the clinical and future commercial success of its singular asset.
View full company profileAbout Stayble Therapeutics
Stayble Therapeutics is a focused, clinical-stage company dedicated to developing STA363, a unique intradiscal injection for chronic pain from lumbar disc herniation (LDH). Its mission is to provide a simple, effective therapeutic option for millions of patients for whom pain medication and physiotherapy have failed, potentially avoiding the need for major surgery. The company's strategy hinges on successfully navigating clinical trials for STA363 to establish it as a leading second-line, minimally invasive treatment. Currently in Phase 1b, Stayble is pre-revenue, with its value and prospects intrinsically tied to the clinical and future commercial success of its singular asset.
View full company profile